Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this trial is to evaluate the incidence of
serious adverse drug reactions when initiating insulin therapy with NovoMix® 30 in subjects
with type 2 diabetes mellitus under normal clinical practice conditions in Sweden.